Targeted drug combo aims to tackle Hard-to-Treat lymphoma
NCT ID NCT04587687
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This phase II trial tests whether combining brentuximab vedotin (a targeted antibody that delivers a toxin to cancer cells) with bendamustine (a chemotherapy drug) can shrink tumors in people with follicular lymphoma that has come back or not responded to prior treatment. The study enrolls adults with CD30-positive follicular lymphoma and measures how many patients achieve a complete response. The goal is to find a safe and effective option for this difficult-to-treat condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
brentuximab vedotin and bendamustine
What this could lead to
If successful, this combination could offer a new treatment option for people with follicular lymphoma that has stopped responding to standard therapies.
What could go wrong
This is a small, early-phase study, so results may not apply to all patients. The drug combination may cause side effects and may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California Davis Comprehensive Cancer Center
RECRUITINGSacramento, California, 95817, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••